293 related articles for article (PubMed ID: 22353786)
1. Bioavailability, antipsoriatic efficacy and tolerability of a new light cream with mometasone furoate 0.1%.
Korting HC; Schöllmann C; Willers C; Wigger-Alberti W
Skin Pharmacol Physiol; 2012; 25(3):133-41. PubMed ID: 22353786
[TBL] [Abstract][Full Text] [Related]
2. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis.
Guenther LC; Poulin YP; Pariser DM
Clin Ther; 2000 Oct; 22(10):1225-38. PubMed ID: 11110233
[TBL] [Abstract][Full Text] [Related]
3. A novel formulation of mometasone furoate in psoriasis patients: a multicenter, randomized, double-blind clinical study.
Berg M; Svensson A; Faergemann J
Adv Ther; 2013 May; 30(5):503-16. PubMed ID: 23709257
[TBL] [Abstract][Full Text] [Related]
4. Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study.
Poulin YP
Cutis; 1999 Jan; 63(1):41-8. PubMed ID: 9951595
[TBL] [Abstract][Full Text] [Related]
5. Comparative potency of formulations of mometasone furoate in terms of inhibition of 'PIRHR' in the forearm skin of normal human subjects measured with laser doppler velocimetry.
Kulhalli P; Chevli T; Karnik R; Sheth M; Mulgaonkar N
Indian J Dermatol Venereol Leprol; 2005; 71(3):170-4. PubMed ID: 16394405
[TBL] [Abstract][Full Text] [Related]
6. Bioequivalence of 0.1% mometasone furoate lotion to 0.1% mometasone furoate hydrogel.
Greive KA; Barnes TM
Australas J Dermatol; 2016 May; 57(2):e39-45. PubMed ID: 25545549
[TBL] [Abstract][Full Text] [Related]
7. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis.
Koo JY; Martin D
Int J Dermatol; 2001 Mar; 40(3):210-2. PubMed ID: 11422529
[No Abstract] [Full Text] [Related]
8. Enhancement of bioavailability by lowering of fat content in topical formulations.
Wirén K; Frithiof H; Sjöqvist C; Lodén M
Br J Dermatol; 2009 Mar; 160(3):552-6. PubMed ID: 19120336
[TBL] [Abstract][Full Text] [Related]
9. Response of cutaneous microcirculation to treatment with mometasone furoate in patients with psoriasis.
Stinco G; Lautieri S; Piccirillo F; Valent F; Patrone P
Clin Exp Dermatol; 2009 Dec; 34(8):915-9. PubMed ID: 19486040
[TBL] [Abstract][Full Text] [Related]
10. In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new.
Kerscher MJ; Hart H; Korting HC; Stalleicken D
Int J Clin Pharmacol Ther; 1995 Apr; 33(4):187-9. PubMed ID: 7620686
[TBL] [Abstract][Full Text] [Related]
11. Comparison of effects of tacrolimus ointment and mometasone furoate cream on the epidermal barrier of patients with atopic dermatitis.
Dähnhardt-Pfeiffer S; Dähnhardt D; Buchner M; Walter K; Proksch E; Fölster-Holst R
J Dtsch Dermatol Ges; 2013 May; 11(5):437-43. PubMed ID: 23551950
[TBL] [Abstract][Full Text] [Related]
12. Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone.
Hoffmann K; Auer T; Stücker M; Hoffmann A; Altmeyer P
J Eur Acad Dermatol Venereol; 1998 Mar; 10(2):137-42. PubMed ID: 9553910
[TBL] [Abstract][Full Text] [Related]
13. Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percent.
Medansky RS; Bressinck R; Cole GW; Deeken JH; Ellis CN; Guin JD; Herndon JH; Lasser AE; Leibsohn E; Menter MA
Cutis; 1988 Nov; 42(5):480-5. PubMed ID: 3058398
[TBL] [Abstract][Full Text] [Related]
14. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. The 194-079 Study Group.
Mandl M; Nolop K; Lutsky BN
Ann Allergy Asthma Immunol; 1997 Sep; 79(3):237-45. PubMed ID: 9305231
[TBL] [Abstract][Full Text] [Related]
15. Mometasone furoate decreases adhesion molecule expression in psoriasis.
Berti E; Cerri A; Marzano AV; Richelda R; Bianchi B; Caputo R
Eur J Dermatol; 1998 Sep; 8(6):421-6. PubMed ID: 9729054
[TBL] [Abstract][Full Text] [Related]
16. Assessment of topical corticosteroid activity using the vasoconstriction assay in healthy volunteers.
Görne RC; Greif C; Metzner U; Wigger-Alberti W; Elsner P
Skin Pharmacol Physiol; 2007; 20(3):133-40. PubMed ID: 17191036
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of activity of different topical corticosteroid creams and ointments using a vasoconstriction assay: superiority of hydrocortisone butyrate over hydrocortisone].
Korting HC; Maslen K; Gross G; Willers C
J Dtsch Dermatol Ges; 2005 May; 3(5):348-53. PubMed ID: 16372801
[TBL] [Abstract][Full Text] [Related]
18. Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study.
Koo J; Cuffie CA; Tanner DJ; Bressinck R; Cornell RC; DeVillez RL; Edwards L; Breneman DL; Piacquadio DJ; Guzzo CA; Monroe EW
Clin Ther; 1998; 20(2):283-91. PubMed ID: 9589819
[TBL] [Abstract][Full Text] [Related]
19. Mometasone furoate 0.1% and salicylic acid 5% vs. mometasone furoate 0.1% as sequential local therapy in psoriasis vulgaris.
Tiplica GS; Salavastru CM
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):905-12. PubMed ID: 19470062
[TBL] [Abstract][Full Text] [Related]
20. Once-daily 0.1% mometasone furoate cream versus twice-daily 0.1% betamethasone valerate cream in the treatment of a variety of dermatoses.
Viglioglia P; Jones ML; Peets EA
J Int Med Res; 1990; 18(6):460-7. PubMed ID: 2292327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
